

## Financial Tear Sheet

### Company Profile

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

### Share Performance

MRUS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$16.00
Change (%)	▼ 0.14 (0.87%)
Volume	4,739
52 Week Low	\$10.15
Market Cap	\$312,991,657
Rolling EPS	-4.72
PE Ratio	0
Shares Outstanding	19,392,296
Data as of 09/19/17 1:05 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

### News & Events

Date	Title
08/30/17	Merus to Participate in Two Investor Conferences in September 2017

Date	Title
09/28/17 2:00 p.m. ET	2017 LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

08/09/17 Merus to Present at the 2017  
Wedbush PacGrow Healthcare  
Conference

07/28/17 U.S. Court of Appeals for the  
Federal Circuit Affirms Merus'  
Inequitable Conduct Claim  
Against Regeneron

## SEC Filings

Filing Date	Form
09/15/17	SC 13G/A
07/20/17	SC 13D/A
07/11/17	6-K
06/16/17	EFFECT

## Supervisory Board

Ton Logtenberg, Ph.D	CEO, Executive Director
Mark Iwicki	Chairman, Non- Executive Director
Wolfgang Berthold, Ph.D.	Non-Executive Director
Anand Mehra, M.D.	Non-Executive Director
Lionel Carnot	Non-Executive Director
John de Koning, Ph.D.	Non-Executive Director
Gregory Perry	Non-Executive Director

## Primary IR Contact

Kimberly Minarovich  
Argot Partners  
Phone: 1 212-600-1902  
E-mail: [kimberly@argotpartners.com](mailto:kimberly@argotpartners.com)

## Management Board

Ton Logtenberg, Ph.D	CEO
Shelley Margetson	CFO